Release date: 2014-10-09

Scientists have discovered a series of lipids that can predict whether a patient will develop symptoms of Alzheimer's disease within three years with an accuracy of more than 90%.

For the first time in decades of research aimed at deciphering Alzheimer's disease, the research team at Georgetown University Medical Center developed and validated a simple blood test that predicts who will be in the next two or three years. The annual experience of cognitive decline is both Alzheimer's disease.

This discovery was published today in the online version of Natural Medicine and will also be published in the printed version in April. For this currently untreated disease, this discovery will delay or even prevent the disease from happening, giving patients new hope that they can wait for new drug development. The number of people suffering from Alzheimer's disease is expected to explode - today's estimated 35.6 million from 35.6 million to 2050.

Howard J. Federoff, MD, a senior researcher at the University and a professor of neurology and executive vice president of health science at Georgetown University Medical Center, said, "This is a very exciting discovery because it finally gave us a A good opportunity to make clinical advances in the research and treatment of Alzheimer's disease."

The team of scientists led by Federoff discovered that 10 lipids, or fat, in the blood circulation can be predicted in the study population with an accuracy of more than 90%, and those who will experience cognitive decline or Atz within three years Symptoms of Haimo's disease.

This five-year study followed 525 older people over the age of 70 in California and New York. Forty-six of them were diagnosed with mild cognitive impairment or mild Alzheimer's disease during the study, and 28 were from normal cognitive decline to impaired memory. Blood tests have shown that people diagnosed with cognitive impairment or Alzheimer's disease or impaired memory have differences in lipids compared to asymptomatic individuals.

Researchers choose this age group because people of this age are most likely to have memory problems within five years.

In addition to Georgetown researchers, other group researchers are from the University of Rochester, the University of California at Irvine, Rochester General Hospital, the University of Rochester Unified Health System, Temple University School of Medicine, and the University of Reeds School of Medicine at Denver. The team identified 10 lipid molecules that predict brain cell damage.

Federoff said: "The perception of these lipids in normal clinical trial participants will allow drug development agencies to study whether experimental drugs can prevent memory impairment at an early stage. In the history of human attempts to change Alzheimer's disease There has been a lot of effort, but sadly, all efforts have failed. One of the reasons is that only people who are already sick are being tested and tested. This is the wrong stage in the study of the cause of the disease."

This is the first of a series of studies. These studies will compare the brain molecular status of people who have no signs of early Alzheimer's disease. The team is conducting a systematic bioanalysis of plasma lipids to genes, transcription and proteinaceous matter – a simple quantitative assay. They have decrypted the genes of each clinical trial participant and collected 12 megabytes of data that is 12 trillion digits of information. The researchers called the lock "the molecular network that defines risk." A key finding is the presence of the APOE4 gene, a known risk factor for Alzheimer's disease, which does not increase the diagnostic accuracy of the test. This is important because it shows that “APOE is a trivial small role in a dangerous population” and that this new lipid test is “more predictive”.

As researchers continue to improve their research, they are testing the number of these lipids in a more diverse population. They believe that “the ideal is that this simple and inexpensive test can be used in almost all clinical trials around the world.” “If you know that you have a risk of cognitive deterioration, this is valuable for life planning, but most The good news is that it is possible to reduce the risk - and this is what everyone is looking for and now there is a breakthrough."

The National Institutes of Health (R01AG030753) and the Department of Defense (W81XWH-09-1-0107) funded the study.

Source: Translation adapted from SelectScience

Silicone Foam Dressing Without Border

Silicone Foam Dressing Without Border,Borderless Silicone Foam Dressing,Foam Dressing Without Border,Silicone Dressing Without Border

Roosin Medical Co.,Ltd , https://www.roosinmedical.com